These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32516572)

  • 1. Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.
    N'Guessan KF; Davis HW; Chu Z; Vallabhapurapu SD; Lewis CS; Franco RS; Olowokure O; Ahmad SA; Yeh JJ; Bogdanov VY; Qi X
    Mol Ther; 2020 Aug; 28(8):1876-1886. PubMed ID: 32516572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer.
    Chu Z; Abu-Baker S; Palascak MB; Ahmad SA; Franco RS; Qi X
    PLoS One; 2013; 8(10):e75507. PubMed ID: 24124494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SapC-DOPS - a Phosphatidylserine-targeted Nanovesicle for selective Cancer therapy.
    N'Guessan KF; Patel PH; Qi X
    Cell Commun Signal; 2020 Jan; 18(1):6. PubMed ID: 31918715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SapC-DOPS nanovesicles as targeted therapy for lung cancer.
    Zhao S; Chu Z; Blanco VM; Nie Y; Hou Y; Qi X
    Mol Cancer Ther; 2015 Feb; 14(2):491-8. PubMed ID: 25670331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
    Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
    J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.
    Wojton J; Chu Z; Mathsyaraja H; Meisen WH; Denton N; Kwon CH; Chow LM; Palascak M; Franco R; Bourdeau T; Thornton S; Ostrowski MC; Kaur B; Qi X
    Mol Ther; 2013 Aug; 21(8):1517-25. PubMed ID: 23732993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors.
    Blanco VM; Chu Z; Vallabhapurapu SD; Sulaiman MK; Kendler A; Rixe O; Warnick RE; Franco RS; Qi X
    Oncotarget; 2014 Aug; 5(16):7105-18. PubMed ID: 25051370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.
    Shrestha P; Ghanwatkar Y; Mahto S; Pramanik N; Mahato RI
    ACS Appl Mater Interfaces; 2024 Jun; 16(23):29686-29698. PubMed ID: 38813771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
    Zhang J; Xu HX; Cho WCS; Cheuk W; Li Y; Huang QH; Yang W; Xian YF; Lin ZX
    J Exp Clin Cancer Res; 2022 Mar; 41(1):90. PubMed ID: 35272669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
    Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
    PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-delivery of autophagy inhibitor and gemcitabine using a pH-activatable core-shell nanobomb inhibits pancreatic cancer progression and metastasis.
    Chen X; Tao Y; He M; Deng M; Guo R; Sheng Q; Wang X; Ren K; Li T; He X; Zang S; Zhang Z; Li M; He Q
    Theranostics; 2021; 11(18):8692-8705. PubMed ID: 34522207
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
    ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
    Logan KA; Nesbitt H; Callan B; Gao J; McKaig T; Taylor M; Love M; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2021 Aug; 165():374-382. PubMed ID: 34038797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Azmi AS; Khan HY; Muqbil I; Aboukameel A; Neggers JE; Daelemans D; Mahipal A; Dyson G; Kamgar M; Al-Hallak MN; Tesfaye A; Kim S; Shidham V; M Mohammad R; Philip PA
    Clin Cancer Res; 2020 Mar; 26(6):1338-1348. PubMed ID: 31831564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
    Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
    Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N; Zhang C; Hinz S; Schwarz MA; Schwarz RE
    J Exp Clin Cancer Res; 2013 Mar; 32(1):12. PubMed ID: 23497499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.